Samsung Bio to Complete Gene Therapy Drug Specialized Manufacturing Facility in Songdo by 2023

Moderna vaccines, contract-manufactured at Samsung Biologics' vaccine plant in Songdo, Incheon Free Economic Zone, are being shipped domestically for the first time. 201.10.28 / Photo by Joint Press Corps

[Asia Economy Reporter Park Hyesook] Samsung Biologics is building a complex manufacturing facility specialized in gene medicines in Songdo International City, Incheon.

The Incheon Free Economic Zone Authority announced on the 3rd that it signed a land sale contract with Samsung Biologics for 10,279㎡ in the advanced industry cluster of Songdo 5 District.

Samsung Biologics plans to produce gene technology-based medicines such as mRNA (messenger ribonucleic acid) vaccines and adenovirus vaccines, as well as raw materials for gene medicines, and conduct research and development on gene delivery platforms at this site.

To this end, a research and development and manufacturing facility with a total floor area of 20,000㎡ will begin construction in the first half of next year and is scheduled to be completed in 2023.

The Incheon Free Economic Zone Authority expects that Samsung Biologics' construction of a next-generation vaccine and therapeutic complex manufacturing facility in Songdo will serve as a driving force to accelerate Songdo's growth as a "global vaccine hub."

In Songdo, Incheon Free Economic Zone, resident companies are expanding their capabilities in infectious disease vaccine and therapeutic research, development, and production in addition to antibody medicine capabilities. Major domestic and international companies such as SL Polgen (DNA vaccine research, development, and production) and Sartorius (vaccine raw material supply) are investing in facilities.

Lee Won-jae, head of the Incheon Free Economic Zone Authority, stated, "The Songdo bio cluster is the city that most proactively realizes the government's core policy task of 'K-Global Vaccine Hub.' We will do our best to attract and support excellent companies so that Songdo becomes a base for innovative growth in Korea's biopharmaceutical sector."

This content was produced with the assistance of AI translation services.